These findings suggest that the potential antineoplastic effects of GLP-1 RA may be more pronounced in individuals with obesity, potentially reflecting the compounds’ dual metabolic and weight-reducing properties. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.